Increased serum levels of IL-6, IL-10, and IL-17A correlate with adverse prognosis in CRC patients undergoing adjuvant chemotherapy and may be useful in monitoring the efficacy of therapy [146,243,245]. This evidence concerns the gene IL10 and colorectal carcinoma.